Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 18/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6496358 | 0.98 | LMNA (0.49) | LMNAHIF1AADRB2ADRB1CHRM3 | |
| SCHEMBL6480958 | 0.93 | LMNA (0.51) | LMNAHIF1AADRB2ADRB1POLB | |
| SCHEMBL6493651 | 0.93 | LMNA (0.47) | LMNAHIF1AADRB2ADRB1POLB | |
| SCHEMBL6482675 | 0.92 | LMNA (0.49) | LMNAHIF1AADRB2ADRB1 | |
| SCHEMBL6496584 | 0.90 | LMNA (0.47) | LMNAHIF1AADRB2ADRB1 | |
| SCHEMBL6489188 | 0.89 | LMNA (0.48) | LMNAHIF1AADRB2ADRB1 | |
| SCHEMBL6480731 | 0.89 | LMNA (0.46) | LMNAHIF1AADRB2ADRB1 | |
| SCHEMBL6493740 | 0.88 | LMNA (0.47) | LMNAHIF1AADRB2ADRB1 | |
| SCHEMBL6480050 | 0.88 | LMNA (0.45) | LMNAHIF1AADRB2ADRB1CHRM3 | |
| SCHEMBL6495955 | 0.87 | LMNA (0.46) | LMNAHIF1AADRB2ADRB1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005092860-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | claimed |
| WO-2005092860-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | disclosed |
| US-20050215542-A1 | Compounds for the treatment of diseases | PFIZER INC | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215542-A1 | Compounds for the treatment of diseases | LTC4S, LTB4R2, EPX | LMNA 1524/4885HIF1A 208/4885ADRB2 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.